JP2007511219A - 移植に好適な幹細胞、その調製およびそれらを含む医薬組成物 - Google Patents

移植に好適な幹細胞、その調製およびそれらを含む医薬組成物 Download PDF

Info

Publication number
JP2007511219A
JP2007511219A JP2006539071A JP2006539071A JP2007511219A JP 2007511219 A JP2007511219 A JP 2007511219A JP 2006539071 A JP2006539071 A JP 2006539071A JP 2006539071 A JP2006539071 A JP 2006539071A JP 2007511219 A JP2007511219 A JP 2007511219A
Authority
JP
Japan
Prior art keywords
cells
cxcr4
population
sdf
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006539071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007511219A5 (enExample
Inventor
ラピドット、ツヴィー
カーン、ジョイ
Original Assignee
イエダ リサーチ アンド ディベロップメント カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イエダ リサーチ アンド ディベロップメント カンパニー リミテッド filed Critical イエダ リサーチ アンド ディベロップメント カンパニー リミテッド
Publication of JP2007511219A publication Critical patent/JP2007511219A/ja
Publication of JP2007511219A5 publication Critical patent/JP2007511219A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
JP2006539071A 2003-11-13 2004-11-08 移植に好適な幹細胞、その調製およびそれらを含む医薬組成物 Pending JP2007511219A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL15886803A IL158868A0 (en) 2003-11-13 2003-11-13 Methods of generating and using stem cells enriched with immature primitive progenitor
PCT/IL2004/001018 WO2005047494A2 (en) 2003-11-13 2004-11-08 Haematopoietic stem cells suitable for transplantation, their preparation and pharmaceutical compositions comprising them

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012032163A Division JP5547221B2 (ja) 2003-11-13 2012-02-16 移植に好適な幹細胞、その調製およびそれらを含む医薬組成物

Publications (2)

Publication Number Publication Date
JP2007511219A true JP2007511219A (ja) 2007-05-10
JP2007511219A5 JP2007511219A5 (enExample) 2011-01-27

Family

ID=34044273

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006539071A Pending JP2007511219A (ja) 2003-11-13 2004-11-08 移植に好適な幹細胞、その調製およびそれらを含む医薬組成物
JP2012032163A Expired - Fee Related JP5547221B2 (ja) 2003-11-13 2012-02-16 移植に好適な幹細胞、その調製およびそれらを含む医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012032163A Expired - Fee Related JP5547221B2 (ja) 2003-11-13 2012-02-16 移植に好適な幹細胞、その調製およびそれらを含む医薬組成物

Country Status (9)

Country Link
US (2) US20080025957A1 (enExample)
EP (1) EP1682653B1 (enExample)
JP (2) JP2007511219A (enExample)
AU (1) AU2004288879B2 (enExample)
CA (1) CA2545409A1 (enExample)
ES (1) ES2534724T3 (enExample)
IL (2) IL158868A0 (enExample)
NO (1) NO335515B1 (enExample)
WO (1) WO2005047494A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015504313A (ja) * 2011-12-02 2015-02-12 フェイト セラピューティクス，インコーポレイテッド 増強された幹細胞組成物
JP2023541168A (ja) * 2020-09-14 2023-09-28 ジェネロス カンパニー， リミテッド 改良された生着可能性を有する幹細胞を調製するための方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
CN101495623B (zh) 2006-03-24 2013-09-11 儿童医疗中心有限公司 调节造血干细胞生长的方法
EP2679221B1 (en) 2006-10-20 2020-09-23 Children's Medical Center Corporation Method to enhance tissue regeneration
WO2008073748A1 (en) 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
CA2682469A1 (en) 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
US8198083B1 (en) 2007-10-31 2012-06-12 William Gunter Loudon Organotypic slices of the central nervous system
WO2009079451A2 (en) 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
EP3031907B1 (en) 2008-11-06 2021-01-06 Indiana University Research and Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
US20120283315A1 (en) 2009-08-28 2012-11-08 Penn Marc S Sdf-1 delivery for treating ischemic tissue
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8834928B1 (en) 2011-05-16 2014-09-16 Musculoskeletal Transplant Foundation Tissue-derived tissugenic implants, and methods of fabricating and using same
MX359398B (es) 2011-09-30 2018-09-27 Bluebird Bio Inc Compuestos para transduccion viral mejorada.
EP3297694A1 (en) 2015-05-21 2018-03-28 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
EP3413896B1 (en) 2016-02-12 2021-03-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
CA3014078A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
GB201807944D0 (en) * 2018-05-16 2018-06-27 Ospedale San Raffaele Srl Compositions and methods for haematopoietic stem cell transplantation
WO2023010068A2 (en) * 2021-07-28 2023-02-02 Cartesian Therapeutics, Inc. Multiprotein-engineered cells secreting a multispecific antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011277A2 (en) * 2001-07-31 2003-02-13 Anormed Inc. Methods to mobilize progenitor/stem cells
WO2003047616A1 (en) * 2001-12-06 2003-06-12 Yeda Research And Development Co. Ltd Migration of hematopoietic stem cells and progenitor cells to th e liver

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
US4879111A (en) * 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4965195A (en) * 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
EP0386476B1 (en) * 1989-02-06 1994-07-13 Mitsubishi Petrochemical Co., Ltd. Process for producing L-alanine
US6326198B1 (en) * 1990-06-14 2001-12-04 Regents Of The University Of Michigan Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5837539A (en) * 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US6447766B1 (en) * 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
US5843780A (en) * 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
WO1996037208A1 (en) * 1995-05-25 1996-11-28 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US6090622A (en) * 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
US6511958B1 (en) * 1997-08-14 2003-01-28 Sulzer Biologics, Inc. Compositions for regeneration and repair of cartilage lesions
IL135068A (en) * 1997-09-29 2004-03-28 Point Therapeutics Inc Stimulation of hematopoietic cells in vitro
US6132708A (en) * 1997-10-10 2000-10-17 Oregon Health Sciences University Liver regeneration using pancreas cells
US6248587B1 (en) * 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
EP1061949B1 (en) * 1998-03-03 2009-07-15 University of Southern California Cytokines and mitogens to inhibit graft-versus-host disease
US6383481B1 (en) * 1998-03-30 2002-05-07 Japan Immunoresearch Laboratories Co., Ltd. Method for transplantation of hemopoietic stem cells
US6184035B1 (en) * 1998-11-18 2001-02-06 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
US6280718B1 (en) * 1999-11-08 2001-08-28 Wisconsin Alumni Reasearch Foundation Hematopoietic differentiation of human pluripotent embryonic stem cells
US6436704B1 (en) * 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
AU2002347563A1 (en) * 2001-12-06 2003-06-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011277A2 (en) * 2001-07-31 2003-02-13 Anormed Inc. Methods to mobilize progenitor/stem cells
WO2003047616A1 (en) * 2001-12-06 2003-06-12 Yeda Research And Development Co. Ltd Migration of hematopoietic stem cells and progenitor cells to th e liver

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015504313A (ja) * 2011-12-02 2015-02-12 フェイト セラピューティクス，インコーポレイテッド 増強された幹細胞組成物
JP2017136094A (ja) * 2011-12-02 2017-08-10 フェイト セラピューティクス，インコーポレイテッド 増強された幹細胞組成物
JP2019047820A (ja) * 2011-12-02 2019-03-28 フェイト セラピューティクス，インコーポレイテッド 増強された幹細胞組成物
JP2019187429A (ja) * 2011-12-02 2019-10-31 フェイト セラピューティクス，インコーポレイテッド 増強された幹細胞組成物
JP2021036918A (ja) * 2011-12-02 2021-03-11 フェイト セラピューティクス，インコーポレイテッド 増強された幹細胞組成物
JP2021191311A (ja) * 2011-12-02 2021-12-16 フェイト セラピューティクス，インコーポレイテッド 増強された幹細胞組成物
JP2023541168A (ja) * 2020-09-14 2023-09-28 ジェネロス カンパニー， リミテッド 改良された生着可能性を有する幹細胞を調製するための方法

Also Published As

Publication number Publication date
IL158868A0 (en) 2004-05-12
AU2004288879B2 (en) 2011-06-16
IL175430A0 (en) 2006-09-05
WO2005047494A2 (en) 2005-05-26
AU2004288879A1 (en) 2005-05-26
ES2534724T3 (es) 2015-04-27
CA2545409A1 (en) 2005-05-26
EP1682653B1 (en) 2015-03-25
US8367057B2 (en) 2013-02-05
JP2012125249A (ja) 2012-07-05
US20080025957A1 (en) 2008-01-31
NO335515B1 (no) 2014-12-22
NO20062709L (no) 2006-08-11
US20110268712A1 (en) 2011-11-03
EP1682653A2 (en) 2006-07-26
IL175430A (en) 2015-01-29
WO2005047494A3 (en) 2005-06-23
JP5547221B2 (ja) 2014-07-09

Similar Documents

Publication Publication Date Title
JP5547221B2 (ja) 移植に好適な幹細胞、その調製およびそれらを含む医薬組成物
Kahn et al. Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation
JP5362659B2 (ja) 化学誘引物質に対する増大させた感受性を有する幹細胞およびそれを産生および使用する方法
US8846393B2 (en) Methods of improving stem cell homing and engraftment
AU2006321172B2 (en) Methods of improving stem cell homing and engraftment
US8252588B2 (en) Stem cells having increased sensitivity to SDF-1 and methods of generating and using same
Kauser et al. Bone marrow-derived progenitors
Duckles et al. Handbook of Experimental Pharmacology
Rosu-Myles Characterization of CXCR4 and SDF-1 in hematopoietic stem and progenitor cell function.
HK1164367A (en) Methods of improving stem cell homing and engraftment

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071031

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100907

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120216

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120307